Completed PHASE2 INTERVENTIONAL 2-arm NCT01497223

MGCD290 and Fluconazole Versus Fluconazole Alone for the Treatment of Moderate to Severe Vulvovaginal Candidiasis

A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Fluconazole Versus Fluconazole And MGCD290 for the Treatment of Moderate to Severe Vulvovaginal Candidiasis

Sponsor: MethylGene Inc.

Conditions Vulvovaginal Candidiasis

Interventions MGCD290

Updated 7 times since 2017 Last updated: Apr 2, 2013 Started: Dec 31, 2011 Primary completion: Apr 30, 2013 Completion: Apr 30, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Vulvovaginal Candidiasis, this trial is completed. The trial is conducted by MethylGene Inc. and has accumulated 7 data snapshots since 2011. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Dec 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

MethylGene Inc.

Data source: MethylGene Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Augusta, United States , Birmingham, United States , Brooklyn, United States , Charleston, United States , Covington, United States , Detroit, United States , Irving, United States , Lake Worth, United States , Las Vegas, United States , Metairie, United States and 9 more locations